Disentangling the Cost of Orphan Drugs Marketed in the United States

The increasing number and high prices of orphan drugs have triggered concern among patients, payers, and policymakers about the affordability of new drugs approved using the incentives set by the Orphan Drug Act (ODA) of 1983. This study evaluated the factors associated to the differences in the tre...

Full description

Bibliographic Details
Main Authors: Hana Althobaiti, Enrique Seoane-Vazquez, Lawrence M. Brown, Marc L. Fleming, Rosa Rodriguez-Monguio
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Healthcare
Subjects:
Online Access:https://www.mdpi.com/2227-9032/11/4/558